Contrast Nephropathy and Nitrates

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media. Iodinated contrast is used during coronary angiography to see the coronary arteries. It has been shown that exposure to this agent may cause kidney injury. CIN usually goes away on its own but in some high risk patients it progresses into renal failure.

This research study offers a new possible option to prevent CIN. We propose that if intravenous nitroglycerin is given before the procedure it may lower the chances of developing contrast-induced nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mt. Sinai Medical Center, Miami
• Collaborator: Florida Heart Research Institute
• Treatments: Nitroglycerin

Criteria

Inclusion Criteria:

1. Patient must be scheduled for percutaneous coronary angiography.

2. Patients must have a Mehran score more or equal to 6 before the procedure.

3. Patients must have baseline creatinine and hemoblogin drawn before the procedure.

4. Signed informed consent.

Exclusion Criteria:

1. Patients on renal replacement therapy before randomization, will be excluded.

2. Being exposed to any types of nitrates 48 hours prior to randomization,

3. History of allergic reaction to any of the components of intravenous nitroglycerin.

4. Exposure to contrast media 4 days prior randomization.

5. Planned revascularization in the next 24 to 48 hours of the first PCI procedure.

6. The patient is hypotensive (<90/60mmHg) at the time of randomization.